Effect of improved glycemic control on health care costs and utilization.

CONTEXT Because of the additional costs associated with improving diabetes management, there is interest in whether improved glycemic control leads to reductions in health care costs, and, if so, when such cost savings occur. OBJECTIVE To determine whether sustained improvements in hemoglobin A(1c) (HbA(1c)) levels among diabetic patients are followed by reductions in health care utilization and costs. DESIGN AND SETTING Historical cohort study conducted in 1992-1997 in a staff-model health maintenance organization (HMO) in western Washington State. PARTICIPANTS All diabetic patients aged 18 years or older who were continuously enrolled between January 1992 and March 1996 and had HbA(1c) measured at least once per year in 1992-1994 (n = 4744). Patients whose HbA(1c) decreased 1% or more between 1992 and 1993 and sustained the decline through 1994 were considered to be improved (n = 732). All others were classified as unimproved (n = 4012). MAIN OUTCOME MEASURES Total health care costs, percentage hospitalized, and number of primary care and specialty visits among the improved vs unimproved cohorts in 1992-1997. RESULTS Diabetic patients whose HbA(1c) measurements improved were similar demographically to those whose levels did not improve but had higher baseline HbA(1c) measurements (10.0% vs 7.7%; P<.001). Mean total health care costs were $685 to $950 less each year in the improved cohort for 1994 (P =.09), 1995 (P =.003), 1996 (P =.002), and 1997 (P =.01). Cost savings in the improved cohort were statistically significant only among those with the highest baseline HbA(1c) levels (>/=10%) for these years but appeared to be unaffected by presence of complications at baseline. Beginning in the year following improvement (1994), utilization was consistently lower in the improved cohort, reaching statistical significance for primary care visits in 1994 (P =.001), 1995 (P<.001), 1996 (P =.005), and 1997 (P =.004) and for specialty visits in 1997 (P =.02). Differences in hospitalization rates were not statistically significant in any year. CONCLUSION Our data suggest that a sustained reduction in HbA(1c) level among adult diabetic patients is associated with significant cost savings within 1 to 2 years of improvement.

[1]  D. Simonson,et al.  Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. , 1998, JAMA.

[2]  E. van Doorslaer,et al.  Statistical analysis of cost outcomes in a randomized controlled clinical trial. , 1994, Health Economics.

[3]  P. O’Connor,et al.  Longitudinal Study Of A Diabetes Education And Care Intervention: Predictors Of Improved Glycemic Control , 1992, The Journal of the American Board of Family Medicine.

[4]  Resource Utilization and Costs of Care in the Diabetes Control and Complications Trial , 1995, Diabetes Care.

[5]  A. Zbrozek,et al.  Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia , 1997, Diabetes Care.

[6]  F Vinicor,et al.  Promoting early diagnosis and treatment of type 2 diabetes: the National Diabetes Education Program. , 2000, JAMA.

[7]  N. Duan.  Smearing Estimate: A Nonparametric Retransformation Method , 1983 .

[8]  R. Gross.  I Am Still Learning , 1975 .

[9]  B. Peterson,et al.  Nurse Case Management To Improve Glycemic Control in Diabetic Patients in a Health Maintenance Organization , 1998, Annals of Internal Medicine.

[10]  E. Wagner,et al.  The use of automated data to identify complications and comorbidities of diabetes: a validation study. , 1999, Journal of clinical epidemiology.

[11]  P. Fishman,et al.  Chronic Care Costs In Managed Care The first single-plan comparison of chronic care costs shows why cost-effective clinical approaches are critical to managed care success. , 1997 .

[12]  E H Wagner,et al.  A population-based approach to diabetes management in a primary care setting: early results and lessons learned. , 1998, Effective clinical practice : ECP.

[13]  W. Manning,et al.  The Cost to Health Plans of Poor Glycemic Control , 1997, Diabetes Care.

[14]  W. Manning,et al.  Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. , 1997, JAMA.

[15]  E H Wagner,et al.  Incidence, outcomes, and cost of foot ulcers in patients with diabetes. , 1999, Diabetes care.

[16]  Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. , 1996, JAMA.

[17]  Ed Wagner.  More Than a Case Manager , 1998, Annals of Internal Medicine.

[18]  C. McBride,et al.  The impact of smoking and quitting on health care use. , 1995, Archives of internal medicine.

[19]  A. Zbrozek,et al.  Model of Complications of NIDDM: I. Model construction and assumptions , 1997, Diabetes Care.

[20]  Brian T. Austin,et al.  Organizing care for patients with chronic illness. , 1996, The Milbank quarterly.

[21]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.

[22]  M. Davidson,et al.  Management of patients with diabetes by nurses with support of subspecialists. , 1995, HMO practice.